News
ACHFF
0.340
-2.83%
-0.010
Arch Biopartners spotlights Phase II LSALT peptide trial for cardiac surgery-associated acute kidney injury at ADA 2026 sessions
PUBT · 5d ago
Arch Biopartners features in American Diabetes Association Thought Leadership Series at Scientific Sessions
PUBT · 5d ago
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Barchart · 5d ago
Arch Biopartners Q2 FY26 net loss narrows to CAD 521,009
PUBT · 06/02 01:37
Arch Biopartners says Royal Columbian Hospital doses first patient in Phase II AKI trial
PUBT · 05/22 10:50
ARCH BIOPARTNERS ANNOUNCES ROYAL COLUMBIAN HOSPITAL HAS DOSED ITS FIRST PATIENT IN ITS PHASE II CARDIAC SURGERY-ASSOCIATED AKI TRIAL
Reuters · 05/22 10:50
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Barchart · 05/22 05:50
Arch Biopartners grants new director 150,000 stock options at $1.05 per share
PUBT · 04/30 12:30
Arch Biopartners says Royal Columbian Hospital begins recruiting for LSALT Phase II trial
PUBT · 04/30 11:09
Arch Biopartners closes CAD 0.6 million private placement of common shares
Reuters · 04/02 09:45
ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT
Reuters · 04/02 09:45
Arch Biopartners announces CAD 0.6 million private placement of common shares
Reuters · 03/30 10:04
ARCH BIOPARTNERS ARRANGES NON-BROKERED PRIVATE PLACEMENT
Reuters · 03/30 10:03
Arch Biopartners signs clinical trial agreement with Fraser Health Authority for Phase II LSALT peptide trial
Reuters · 03/24 13:13
ARCH BIOPARTNERS AND THE FRASER HEALTH AUTHORITY ENTER INTO A CLINICAL TRIAL AGREEMENT FOR THE PHASE II CARDIAC SURGERY-ASSOCIATED AKI TRIAL
Reuters · 03/24 13:13
St. Michael’s Hospital begins dosing patients in Arch Biopartners’ 240-patient Phase II LSALT peptide trial
Reuters · 03/20 11:17
ARCH BIOPARTNERS ANNOUNCES ST. MICHAEL’S HOSPITAL COMMENCES PATIENT DOSING IN THE PHASE II CS-AKI TRIAL OF LSALT PEPTIDE
Reuters · 03/20 11:05
Arch Biopartners’ Q1 net loss widens to CAD 1.6 million (3.7x)
Reuters · 03/03 03:01
Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD
TipRanks · 02/09 12:45
Arch Biopartners Advances IL-32 Drug Candidate Toward Clinical Trials for Diabetic Kidney Disease
Reuters · 02/09 12:29
More
Webull provides a variety of real-time ACHFF stock news. You can receive the latest news about Arch Biopartners through multiple platforms. This information may help you make smarter investment decisions.
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.